Söndag 22 December | 07:05:47 Europe / Stockholm

Bifogade filer

Prenumeration

2023-02-28 07:40:00

Redeye revisits LIDDS following a change of analyst, a change of company CEO, and the outcome of a newly conducted rights issue. We endorse the company’s robust new focus on the business development of its portfolio, which should establish LIDDS in an encouraging position to seal a licensing deal in 2023.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/